Close Menu

NEW YORK – Kevin Ness, the CEO of gene editing company Inscripta, has long had a vision of doing for genome writing what Illumina did for genome reading — to make genome engineering as innovative, as scalable, and as widespread as genome sequencing is today.

To do that, Inscripta has been developing an integrated suite of software, reagents, nucleases, and an automated benchtop instrument that are designed to work together in a way that seems to combine the principles behind CRISPR gene editing, single-cell genomics, and synthetic biology into one technological platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.